Roscoe Brady, MD, PhD (10/11/1923-6/13/2016), first introduced Jeff Galvin to viral vectors in 2007, and his expertise, advice, support, and encouragement were key to the founding and growth of American Gene Technologies™ (AGT). Dr. Brady was both a brilliant physician and an accomplished research scientist, having spent more than 50 years researching hereditary metabolic storage diseases (also known as lipid or lysosomal storage disorders).

Dr. Brady is probably best known for having co-discovered the enzymatic defects in Gaucher disease, which subsequently led to his development of a successful enzyme replacement therapy (ERT). According to the National Institute of Neurological Disorders and Stroke (NINDS), “His work has defined much of what is known about the biochemistry, enzymatic bases, and metabolic defects of these disorders, and he has inspired colleagues throughout the world to define the causes of many other related disorders and to pursue further investigations in this field”.

Dr. Brady served as Chairman of the AGT scientific advisory board until his passing in 2016.  His passion and commitment to finding solutions for patients continue to be an inspiration to all of us at American Gene Technologies.